126 related articles for article (PubMed ID: 31298052)
1. High NF-E2-related factor 2 expression predicts poor prognosis in patients with lung cancer: a meta-analysis of cohort studies.
Yang Q; Deng H; Xia H; Xu M; Pan G; Mao J; Tao S; Yamanaka K; An Y
Free Radic Res; 2020 Dec; 54(11-12):790-798. PubMed ID: 31298052
[TBL] [Abstract][Full Text] [Related]
2. [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].
Zhu X; Liang L; Liu C; Yin W; Chen S; Cao B
Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):155-62. PubMed ID: 24581168
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
Wang Q; Xu L; Wang G; Chen L; Li C; Jiang X; Gao H; Yang B; Tian W
PLoS One; 2020; 15(11):e0241241. PubMed ID: 33186371
[TBL] [Abstract][Full Text] [Related]
4. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
Almeida M; Soares M; Ramalhinho AC; Moutinho JF; Breitenfeld L; Pereira L
Breast Cancer Res Treat; 2020 Feb; 179(3):523-532. PubMed ID: 31745730
[TBL] [Abstract][Full Text] [Related]
7. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis.
Zhang R; Tian P; Chen B; Wang T; Li W
Postgrad Med; 2019 Apr; 131(3):199-206. PubMed ID: 30798634
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
[TBL] [Abstract][Full Text] [Related]
11. Association between 18F-FDG uptake in PET/CT, Nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.
Park SY; Lee SJ; Han JH; Koh YW
Neoplasma; 2019 Jul; 66(4):619-626. PubMed ID: 30868898
[TBL] [Abstract][Full Text] [Related]
12. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis.
Guo Y; Shen L
Thorac Cancer; 2017 Nov; 8(6):558-564. PubMed ID: 28766861
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
16. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
17. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
[TBL] [Abstract][Full Text] [Related]
18. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
[TBL] [Abstract][Full Text] [Related]
19. The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis.
Gong T; Liu J; Jiang J; Zhai YF; Wu CM; Ma C; Wen BL; Yan XY; Zhang X; Wang DM; Lu Q; Qu YL
Cell Mol Biol (Noisy-le-grand); 2019 Jan; 65(1):89-93. PubMed ID: 30782303
[TBL] [Abstract][Full Text] [Related]
20. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
